The market is mainly driven by the sales of major human vaccines such as Prevnar 13, Gardasil, ProQuad, Varivax, M-M-R II, polio/pertussis/Hib vaccines, and influenza vaccines.
There has been increasing government interest in various parts of the world due to sudden outbreaks of major diseases such as Ebola, Zika virus, chikungunya, avian influenza, the H1N1 virus, and COVID-19; these outbreaks have been the primary reason for the recent market growth.
Regulations are in place to check outbreaks due to tourists carrying the diseases, and vaccines have become a requirement in some countries and are highly recommended for international travelers. Various government programs and increased public awareness regarding viral diseases such as hepatitis, measles-mumps-rubella (MMR), and polio have augmented vaccination rates in various countries. The growth in this industry is also driven by the global population increases and the acceptance of adult vaccines.
Vaccines can significantly reduce the burden of many diseases and increase life expectancy through prevention. The introduction of newer vaccines covering many diseases is another factor pushing the market towards significant growth. New product offerings to address unmet needs, contingency planning for pandemic infections, awareness of disease prevention, improving economic conditions in developing countries, and increasing interest and investments from major pharmaceutical companies are shaping the vaccine market.
Growth in the vaccine market is anticipated on the basis of technological advancements with respect to the development of novel vaccines towards emerging infectious diseases, cancers, and allergies. Continuous improvements in vaccine design, delivery technologies, and manufacturing will also help market growth.
The global animal vaccine market is also growing in importance. Increasing demand for livestock products and an increase in pet ownership are the foremost reasons for increasing vaccination in animals. Significant developments in biotechnology, informatics, and information systems have prompted better planning and execution of animal disease prevention in many countries.
In terms of geography, North America accounted for a major share in the total vaccine market, along with Asia-Pacific. The North American market is driven by strict regulations and high awareness, whereas the Asia-Pacific market is driven by high demand due to the broad prevalence of diseases such as influenza and hepatitis.
Key Topics Covered:
Chapter 1 Introduction
Chapter 2 Summary and Highlights
Chapter 3 Market and Technology Background
Definitions
Immune System and Vaccines
How Vaccines Work?
Types of Immunity
Advantages of Vaccination
History of Vaccines
Types of Vaccines
Attenuated (Live) Vaccines
Inactivated (Killed) Vaccines
Toxoid Vaccines
Subunit Vaccines
Conjugate Vaccines
Recombinant Vector Vaccines
DNA Vaccines
RNA Vaccines
Adjuvants and Excipients
Pathogen Components
Particulate Adjuvants
Infectious Diseases Preventable by Vaccines
Human Diseases
Viral Diseases
Bacterial Diseases
Animal Diseases
Food-Producing Animals
Companion Animals
Other Animals
Rapid Manufacturing for Pandemics
Types of Vaccine Manufacturing Methods
Plant-Based Vaccines
Egg-Based Vaccine Manufacturing
Cell-Based Vaccines
Investigational Vaccine Manufacturing Methods
Clinical Development of Vaccines
Clinical Development of Pandemic Vaccines
Laws and Regulations
Vaccine Distribution in the Case of Pandemic Diseases
Government Initiatives
Recent Technologies and Companies
Technological Advancements Such as Rapid Manufacturing
Rising Immunization across the Globe
Government Support for Vaccine Development
Lack of Awareness in Low-Income Countries
Opportunities
RNA Vaccination
Rise of Antibiotic Resistance
Current Situation
Dynamics of the Market for Human Vaccines
Dynamics of the Market for Animal Vaccines
Regulatory Aspects
World Health Organization (WHO) Prequalified Vaccines
New Product Approvals
Recalls
Vaccine Shortage
Significant Regulatory Developments in Vaccine-Preventable Disease Products
Chapter 4 Market Breakdown by Human Vaccine
Human Vaccines by Type
Attenuated (Live) Vaccines
Inactivated Vaccines
Conjugate Vaccines
DNA/rDNA Vaccines
Subunit Vaccines
Toxoid Vaccines
Other/Combination Vaccines
Vaccines by Age Group
Pediatric Vaccines
Vaccines for Adolescents and Adults
Vaccines for the Geriatric Population
Vaccine by Disease Type
Diptheria
Influenza
Hepatitis A
Measles
Rotavirus
Chickenpox
Other Diseases and Combination Vaccines
Outbreak of Diseases
Vaccines by Delivery Route
Intramuscular Injection
Intradermal Injection
Mucosal Vaccination
Nanopatch
Chapter 5 Market Breakdown by Animal Vaccine
Animal Vaccines
Market by Type
Chapter 6 Market Breakdown by Region
North America
United States
Canada
Europe
Germany
France
United Kingdom
Italy
Rest of Europe
Asia-Pacific
China
Japan
India
Rest of APAC
Rest of the World
Chapter 7 COVID-19 Impact on Present and Future
Impact of COVID-19 on Vaccine Supplies
Massive Impact on Lower-Income Countries Threatens More Disease Outbreaks
Chapter 8 Company Profiles
Abbott Laboratories
Astellas Pharma Inc.
Astrazeneca Plc
Baxter International Inc.
Bayer Animal Health
Bharat Biotech International Ltd.
Biological E. Ltd.
Bio-Manguinhos
Bioproperties Pty Ltd.
Boehringer Ingelheim Gmbh
Bul Bio National Center Of Infectious And Parasitic Diseases Ltd. (Bb-Ncipd Ltd.)
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the Drug...
Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) ("Genomma" or "the Company"), today announced its results for the first quarter of 2024. All figures included herein are stated in nominal Mexican pesos and have been prepared in accordance with...
The First Bancshares, Inc. ("FBMS" or "the Company") , holding company for The First Bank, (www.thefirstbank.com) reported today financial results for the quarter ended March 31, 2024.
Highlights for the Quarter:
Net income available to common...
Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specializing in thedevelopment oftherapeutics for age-related...
Alamos Gold Inc. ("Alamos" or the "Company") today reported its financial results for the quarter ended March 31, 2024. "We delivered another strong start to the year across a number of fronts, following a record performance in 2023. Costs...